BrainAurora Medical Technology Co., Ltd. (Ticker: 6681 HK) is a Chinese biotechnology company specializing in digital therapeutics for cognitive impairments. Founded in 2012, the company integrates neuroscience with artificial intelligence to develop products for diagnosing and treating cognitive disorders related to vascular diseases, neurodegenerative conditions, mental illnesses, and developmental defects. Its flagship product, "66nao," supports clinical assessment, treatment, and outcome management and is used in over 120 cognitive centers across China.

The company will list on the Hong Kong Stock Exchange on January 8, 2025, offering 181.11 million shares at HKD 3.22 per share, aiming to raise HKD 583.2 million (USD 74.97 million). The net proceeds will be used to enhance research and development, fund clinical trials, assist hospitals in setting up cognitive centers, and strengthen AI capabilities. Joint sponsors include SPDB International Capital and China International Capital Corporation. Despite reporting losses in recent years, BrainAurora aims to leverage its IPO proceeds to expand its market presence and further develop its cognitive health solutions.